US 11,717,486 B2
Highly stable formulations of thyroid hormone in soft capsules
Simone Carucci, Lugano (CH); Maurizio Marchiorri, Lugano (CH); Marco Pontiggia, Lugano (CH); and Tiziano Fossati, Lugano (CH)
Assigned to ALTERGON S.A., Lugano (CH)
Appl. No. 16/970,694
Filed by ALTERGON S.A., Lugano (CH)
PCT Filed Mar. 6, 2019, PCT No. PCT/EP2019/055547
§ 371(c)(1), (2) Date Aug. 18, 2020,
PCT Pub. No. WO2019/174990, PCT Pub. Date Sep. 19, 2019.
Claims priority of application No. 102018000003615 (IT), filed on Mar. 15, 2018.
Prior Publication US 2020/0375909 A1, Dec. 3, 2020
Int. Cl. A61K 9/48 (2006.01); A61K 31/198 (2006.01); A61K 47/36 (2006.01)
CPC A61K 9/4866 (2013.01) [A61K 9/485 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 31/198 (2013.01); A61K 47/36 (2013.01)] 16 Claims
 
1. A soft capsule comprising:
an interior fill,
wherein said fill comprises one or more thyroid hormones and a high-amylose starch,
wherein said high-amylose starch comprises between 50 and 85% by weight of amylose with respect to the total weight of the starch.